ID   EPM2A_HUMAN             Reviewed;         331 AA.
AC   O95278; B3KMU5; B4DRZ2; O95483; Q5T3F5; Q6IS15; Q8IU96; Q8IX24;
AC   Q8IX25; Q9BS66; Q9UEN2;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 2.
DT   15-MAR-2017, entry version 152.
DE   RecName: Full=Laforin;
DE            EC=3.1.3.-;
DE            EC=3.1.3.16;
DE            EC=3.1.3.48;
DE   AltName: Full=Glucan phosphatase;
DE   AltName: Full=Lafora PTPase;
DE            Short=LAFPTPase;
GN   Name=EPM2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), ALTERNATIVE SPLICING,
RP   PROBABLE FUNCTION, TISSUE SPECIFICITY, VARIANTS EPM2 CYS-108; SER-279
RP   AND LEU-293, AND VARIANT ASP-114.
RX   PubMed=9771710; DOI=10.1038/2470;
RA   Minassian B.A., Lee J.R., Herbrick J.-A., Huizenga J., Soder S.,
RA   Mungall A.J., Dunham I., Gardner R., Fong C.G., Carpenter S.,
RA   Jardim L., Satishchandra P., Andermann E., Snead O.C. III,
RA   Lopes-Cendes I., Tsui L.-C., Delgado-Escueta A.V., Rouleau G.A.,
RA   Scherer S.W.;
RT   "Mutations in a gene encoding a novel protein tyrosine phosphatase
RT   cause progressive myoclonus epilepsy.";
RL   Nat. Genet. 20:171-174(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTIONAL CHARACTERIZATION,
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS EPM2 HIS-171
RP   AND LEU-293.
RC   TISSUE=Fetal brain;
RX   PubMed=11001928; DOI=10.1093/oxfordjournals.hmg.a018916;
RA   Ganesh S., Agarwala K.L., Ueda K., Akagi T., Shoda K., Usui T.,
RA   Hashikawa T., Osada H., Delgado-Escueta A.V., Yamakawa K.;
RT   "Laforin, defective in the progressive myoclonus epilepsy of Lafora
RT   type, is a dual-specificity phosphatase associated with
RT   polyribosomes.";
RL   Hum. Mol. Genet. 9:2251-2261(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Lee J.R., Scherer S.W.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), AND NUCLEOTIDE SEQUENCE [MRNA]
RP   OF 25-331 (ISOFORM 4).
RC   TISSUE=Cerebellum, and Fetal brain;
RA   Ganesh S., Yamakawa K.;
RT   "Cloning of differentially spliced transcripts of the EPM2A gene.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 7 AND 8).
RC   TISSUE=Fetal brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6).
RC   TISSUE=Hypothalamus, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 82-331 (ISOFORMS 1 AND 2), AND VARIANTS
RP   EPM2 HIS-171; ILE-194; SER-279 AND ASN-294.
RX   PubMed=9931343; DOI=10.1093/hmg/8.2.345;
RA   Serratosa J.M., Gomez-Garre P., Gallardo M.E., Anta B.,
RA   de Bernabe D.B., Lindhout D., Augustijn P.B., Tassinari C.A.,
RA   Malafosse R.M., Topcu M., Grid D., Dravet C., Berkovic S.F.,
RA   de Cordoba S.R.;
RT   "A novel protein tyrosine phosphatase gene is mutated in progressive
RT   myoclonus epilepsy of the Lafora type (EPM2).";
RL   Hum. Mol. Genet. 8:345-352(1999).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11220751;
RX   DOI=10.1002/1531-8249(20010201)49:2<271::AID-ANA52>3.3.CO;2-4;
RA   Minassian B.A., Andrade D.M., Ianzano L., Young E.J., Chan E.,
RA   Ackerley C.A., Scherer S.W.;
RT   "Laforin is a cell membrane and endoplasmic reticulum-associated
RT   protein tyrosine phosphatase.";
RL   Ann. Neurol. 49:271-275(2001).
RN   [11]
RP   ALTERNATIVE SPLICING, AND SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=11883934; DOI=10.1006/bbrc.2002.6590;
RA   Ganesh S., Suzuki T., Yamakawa K.;
RT   "Alternative splicing modulates subcellular localization of laforin.";
RL   Biochem. Biophys. Res. Commun. 291:1134-1137(2002).
RN   [12]
RP   GLYCOGEN-BINDING, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT
RP   EPM2 GLY-32, ACTIVE SITE, AND MUTAGENESIS OF LYS-87 AND CYS-266.
RX   PubMed=11739371; DOI=10.1074/jbc.C100686200;
RA   Wang J., Stuckey J.A., Wishart M.J., Dixon J.E.;
RT   "A unique carbohydrate binding domain targets the Lafora disease
RT   phosphatase to glycogen.";
RL   J. Biol. Chem. 277:2377-2380(2002).
RN   [13]
RP   INTERACTION WITH EPM2AIP1.
RX   PubMed=12782127; DOI=10.1016/S0888-7543(03)00094-6;
RA   Ianzano L., Zhao X.C., Minassian B.A., Scherer S.W.;
RT   "Identification of a novel protein interacting with laforin, the EPM2A
RT   progressive myoclonus epilepsy gene product.";
RL   Genomics 81:579-587(2003).
RN   [14]
RP   INTERACTION WITH HIRIP5.
RX   PubMed=12915448; DOI=10.1093/hmg/ddg253;
RA   Ganesh S., Tsurutani N., Suzuki T., Ueda K., Agarwala K.L., Osada H.,
RA   Delgado-Escueta A.V., Yamakawa K.;
RT   "The Lafora disease gene product laforin interacts with HIRIP5, a
RT   phylogenetically conserved protein containing a NifU-like domain.";
RL   Hum. Mol. Genet. 12:2359-2368(2003).
RN   [15]
RP   SELF-INTERACTION, INTERACTION WITH PPP1R3C, MUTAGENESIS OF ASP-235 AND
RP   CYS-266, AND CHARACTERIZATION OF VARIANTS EPM2 GLY-32; LEU-84;
RP   CYS-108; ILE-194; SER-240; SER-279; LEU-293; ASN-294 AND LEU-301.
RX   PubMed=14532330; DOI=10.1093/hmg/ddg340;
RA   Fernandez-Sanchez M.E., Criado-Garcia O., Heath K.E.,
RA   Garcia-Fojeda B., Medrano-Fernandez I., Gomez-Garre P., Sanz P.,
RA   Serratosa J.M., Rodriguez de Cordoba S.;
RT   "Laforin, the dual-phosphatase responsible for Lafora disease,
RT   interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1
RT   that enhances glycogen accumulation.";
RL   Hum. Mol. Genet. 12:3161-3171(2003).
RN   [16]
RP   BINDING TO LAFORA BODIES, CHARACTERIZATION OF VARIANTS EPM2 PRO-25;
RP   LYS-28; GLY-32 AND LEU-88, AND CHARACTERIZATION OF VARIANT PRO-46.
RX   PubMed=14706656; DOI=10.1016/j.bbrc.2003.12.043;
RA   Ganesh S., Tsurutani N., Suzuki T., Hoshii Y., Ishihara T.,
RA   Delgado-Escueta A.V., Yamakawa K.;
RT   "The carbohydrate-binding domain of Lafora disease protein targets
RT   Lafora polyglucosan bodies.";
RL   Biochem. Biophys. Res. Commun. 313:1101-1109(2004).
RN   [17]
RP   INTERACTION WITH NHLRC1, AND POLYUBIQUITINATION.
RX   PubMed=15930137; DOI=10.1073/pnas.0503285102;
RA   Gentry M.S., Worby C.A., Dixon J.E.;
RT   "Insights into Lafora disease: malin is an E3 ubiquitin ligase that
RT   ubiquitinates and promotes the degradation of laforin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8501-8506(2005).
RN   [18]
RP   FUNCTION AS A GLUCAN PHOSPHATASE, AND INTERACTION WITH PPP1R3B;
RP   PPP1R3C AND PPP1R3D.
RX   PubMed=16901901; DOI=10.1074/jbc.M606117200;
RA   Worby C.A., Gentry M.S., Dixon J.E.;
RT   "Laforin, a dual specificity phosphatase that dephosphorylates complex
RT   carbohydrates.";
RL   J. Biol. Chem. 281:30412-30418(2006).
RN   [19]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17908927; DOI=10.1101/gad.1553207;
RA   Cheng A., Zhang M., Gentry M.S., Worby C.A., Dixon J.E., Saltiel A.R.;
RT   "A role for AGL ubiquitination in the glycogen storage disorders of
RT   Lafora and Cori's disease.";
RL   Genes Dev. 21:2399-2409(2007).
RN   [20]
RP   FUNCTION, HOMODIMERIZATION, HETERODIMERIZATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18617530; DOI=10.1093/hmg/ddn199;
RA   Dubey D., Ganesh S.;
RT   "Modulation of functional properties of laforin phosphatase by
RT   alternative splicing reveals a novel mechanism for the EPM2A gene in
RT   Lafora progressive myoclonus epilepsy.";
RL   Hum. Mol. Genet. 17:3010-3020(2008).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH PPP1R3C.
RX   PubMed=18070875; DOI=10.1074/jbc.M708712200;
RA   Worby C.A., Gentry M.S., Dixon J.E.;
RT   "Malin decreases glycogen accumulation by promoting the degradation of
RT   protein targeting to glycogen (PTG).";
RL   J. Biol. Chem. 283:4069-4076(2008).
RN   [22]
RP   FUNCTION, AND COMPLEX FORMATION WITH NHLRC1 AND HSP70.
RX   PubMed=19036738; DOI=10.1093/hmg/ddn398;
RA   Garyali P., Siwach P., Singh P.K., Puri R., Mittal S., Sengupta S.,
RA   Parihar R., Ganesh S.;
RT   "The malin-laforin complex suppresses the cellular toxicity of
RT   misfolded proteins by promoting their degradation through the
RT   ubiquitin-proteasome system.";
RL   Hum. Mol. Genet. 18:688-700(2009).
RN   [23]
RP   INTERACTION WITH MAPT.
RX   PubMed=19542233; DOI=10.1074/jbc.M109.009688;
RA   Puri R., Suzuki T., Yamakawa K., Ganesh S.;
RT   "Hyperphosphorylation and aggregation of Tau in laforin-deficient
RT   mice, an animal model for Lafora disease.";
RL   J. Biol. Chem. 284:22657-22663(2009).
RN   [24]
RP   FUNCTION.
RX   PubMed=20453062; DOI=10.1093/hmg/ddq190;
RA   Aguado C., Sarkar S., Korolchuk V.I., Criado O., Vernia S., Boya P.,
RA   Sanz P., de Cordoba S.R., Knecht E., Rubinsztein D.C.;
RT   "Laforin, the most common protein mutated in Lafora disease, regulates
RT   autophagy.";
RL   Hum. Mol. Genet. 19:2867-2876(2010).
RN   [25]
RP   PHOSPHORYLATION AT SER-25, AND MUTAGENESIS OF SER-25; SER-168; THR-187
RP   AND THR-194.
RX   PubMed=21728993; DOI=10.1042/BJ20110150;
RA   Roma-Mateo C., Solaz-Fuster Mdel C., Gimeno-Alcaniz J.V.,
RA   Dukhande V.V., Donderis J., Worby C.A., Marina A., Criado O.,
RA   Koller A., Rodriguez De Cordoba S., Gentry M.S., Sanz P.;
RT   "Laforin, a dual-specificity phosphatase involved in Lafora disease,
RT   is phosphorylated at Ser25 by AMP-activated protein kinase.";
RL   Biochem. J. 439:265-275(2011).
RN   [26]
RP   INTERACTION WITH PRDM8.
RX   PubMed=22961547; DOI=10.1093/brain/aws205;
RA   Turnbull J., Girard J.M., Lohi H., Chan E.M., Wang P., Tiberia E.,
RA   Omer S., Ahmed M., Bennett C., Chakrabarty A., Tyagi A., Liu Y.,
RA   Pencea N., Zhao X., Scherer S.W., Ackerley C.A., Minassian B.A.;
RT   "Early-onset Lafora body disease.";
RL   Brain 135:2684-2698(2012).
RN   [27]
RP   ALTERNATIVE SPLICING (ISOFORMS 4; 5; 6; 7 AND 9).
RX   PubMed=22036712; DOI=10.1016/j.ygeno.2011.10.001;
RA   Dubey D., Parihar R., Ganesh S.;
RT   "Identification and characterization of novel splice variants of the
RT   human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.";
RL   Genomics 99:36-43(2012).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH PPP1R3D.
RX   PubMed=23624058; DOI=10.1016/j.biocel.2013.04.019;
RA   Rubio-Villena C., Garcia-Gimeno M.A., Sanz P.;
RT   "Glycogenic activity of R6, a protein phosphatase 1 regulatory
RT   subunit, is modulated by the laforin-malin complex.";
RL   Int. J. Biochem. Cell Biol. 45:1479-1488(2013).
RN   [29]
RP   MUTAGENESIS OF 109-CYS-CYS-110; CYS-123; CYS-169; CYS-205; CYS-250;
RP   CYS-266; CYS-329 AND 329-CYS--CYS-331.
RX   PubMed=23922729; DOI=10.1371/journal.pone.0069523;
RA   Sanchez-Martin P., Raththagala M., Bridges T.M., Husodo S.,
RA   Gentry M.S., Sanz P., Roma-Mateo C.;
RT   "Dimerization of the glucan phosphatase laforin requires the
RT   participation of cysteine 329.";
RL   PLoS ONE 8:E69523-E69523(2013).
RN   [30]
RP   VARIANTS EPM2 LEU-84; SER-240 AND LEU-301.
RX   PubMed=11175283; DOI=10.1038/sj.ejhg.5200571;
RA   Gomez-Garre P., Sanz Y., Rodriguez de Cordoba S.R., Serratosa J.M.;
RT   "Mutational spectrum of the EPM2A gene in progressive myoclonus
RT   epilepsy of Lafora: high degree of allelic heterogeneity and
RT   prevalence of deletions.";
RL   Eur. J. Hum. Genet. 8:946-954(2000).
RN   [31]
RP   VARIANT PRO-46.
RX   PubMed=11735300; DOI=10.1006/mcpr.2001.0371;
RA   Ganesh S., Shoda K., Amano K., Uchiyama A., Kumada S., Moriyama N.,
RA   Hirose S., Yamakawa K.;
RT   "Mutation screening for Japanese Lafora's disease patients:
RT   identification of novel sequence variants in the coding and upstream
RT   regulatory regions of EPM2A gene.";
RL   Mol. Cell. Probes 15:281-289(2001).
RN   [32]
RP   VARIANTS EPM2 PRO-25; CYS-108; HIS-171 AND LEU-293, AND
RP   CHARACTERIZATION OF VARIANTS EPM2 GLY-32; CYS-108; ILE-194; SER-279
RP   AND ASN-294.
RX   PubMed=12019207; DOI=10.1093/hmg/11.11.1263;
RA   Ganesh S., Delgado-Escueta A.V., Suzuki T., Francheschetti S.,
RA   Riggio C., Avanzini G., Rabinowicz A., Bohlega S., Bailey J.,
RA   Alonso M.E., Rasmussen A., Thomson A.E., Ochoa A., Prado A.J.,
RA   Medina M.T., Yamakawa K.;
RT   "Genotype-phenotype correlations for EPM2A mutations in Lafora's
RT   progressive myoclonus epilepsy: exon 1 mutations associate with an
RT   early-onset cognitive deficit subphenotype.";
RL   Hum. Mol. Genet. 11:1263-1271(2002).
RN   [33]
RP   VARIANT EPM2 ALA-187.
RX   PubMed=12560877; DOI=10.1007/s100380300006;
RA   Ki C.S., Kong S.Y., Seo D.W., Hong S.B., Kim H.J., Kim J.W.;
RT   "Two novel mutations in the EPM2A gene in a Korean patient with
RT   Lafora's progressive myoclonus epilepsy.";
RL   J. Hum. Genet. 48:51-54(2003).
RN   [34]
RP   VARIANT EPM2 PRO-91.
RX   PubMed=15009235; DOI=10.1111/j.0013-9580.2004.33203.x;
RA   Annesi G., Sofia V., Gambardella A., Ciro Candiano I.C., Spadafora P.,
RA   Annesi F., Cutuli N., De Marco E.V., Civitelli D., Carrideo S.,
RA   Tarantino P., Barone R., Zappia M., Quattrone A.;
RT   "A novel exon 1 mutation in a patient with atypical Lafora progressive
RT   myoclonus epilepsy seen as childhood-onset cognitive deficit.";
RL   Epilepsia 45:294-295(2004).
RN   [35]
RP   VARIANTS EPM2 PRO-91; HIS-171 AND SER-279.
RX   PubMed=14722920; DOI=10.1002/humu.10306;
RA   Ianzano L., Young E.J., Zhao X.C., Chan E.M., Rodriguez M.T.,
RA   Torrado M.V., Scherer S.W., Minassian B.A.;
RT   "Loss of function of the cytoplasmic isoform of the protein laforin
RT   (EPM2A) causes Lafora progressive myoclonus epilepsy.";
RL   Hum. Mutat. 23:170-176(2004).
RN   [36]
RP   VARIANT PRO-46.
RX   PubMed=16021330; DOI=10.1007/s10038-005-0263-7;
RA   Singh S., Suzuki T., Uchiyama A., Kumada S., Moriyama N., Hirose S.,
RA   Takahashi Y., Sugie H., Mizoguchi K., Inoue Y., Kimura K.,
RA   Sawaishi Y., Yamakawa K., Ganesh S.;
RT   "Mutations in the NHLRC1 gene are the common cause for Lafora disease
RT   in the Japanese population.";
RL   J. Hum. Genet. 50:347-352(2005).
RN   [37]
RP   VARIANTS EPM2 ASN-140; TYR-148; LYS-210 AND TRP-310, AND
RP   CHARACTERIZATION OF VARIANT EPM2 TRP-310.
RX   PubMed=18311786; DOI=10.1002/humu.20737;
RA   Singh S., Satishchandra P., Shankar S.K., Ganesh S.;
RT   "Lafora disease in the Indian population: EPM2A and NHLRC1 gene
RT   mutations and their impact on subcellular localization of laforin and
RT   malin.";
RL   Hum. Mutat. 29:E1-12(2008).
CC   -!- FUNCTION: Has both dual-specificity protein phosphatase and glucan
CC       phosphatase activities. Together with the E3 ubiquitin ligase
CC       NHLRC1/malin, appears to be involved in the clearance of toxic
CC       polyglucosan and protein aggregates via multiple pathways.
CC       Dephosphorylates phosphotyrosine, phosphoserine and
CC       phosphothreonine substrates in vitro. Has also been shown to
CC       dephosphorylate MAPT. Shows strong phosphatase activity towards
CC       complex carbohydrates in vitro, avoiding glycogen
CC       hyperphosphorylation which is associated with reduced branching
CC       and formation of insoluble aggregates. Forms a complex with
CC       NHLRC1/malin and HSP70, which suppresses the cellular toxicity of
CC       misfolded proteins by promoting their degradation through the
CC       ubiquitin-proteasome system (UPS). Acts as a scaffold protein to
CC       facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Also
CC       promotes proteasome-independent protein degradation through the
CC       macroautophagy pathway. Isoform 2, an inactive phosphatase, could
CC       function as a dominant-negative regulator for the phosphatase
CC       activity of isoform 1. {ECO:0000269|PubMed:11001928,
CC       ECO:0000269|PubMed:11220751, ECO:0000269|PubMed:16901901,
CC       ECO:0000269|PubMed:18070875, ECO:0000269|PubMed:18617530,
CC       ECO:0000269|PubMed:19036738, ECO:0000269|PubMed:20453062,
CC       ECO:0000269|PubMed:23624058}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC   -!- SUBUNIT: Interacts with itself; however no biological function has
CC       been identified for the dimer. Interacts with PPP1R3B, PPP1R3C,
CC       HIRIP5, and EPM2AIP1. Binds glycogen and Lafora bodies. Interacts
CC       with NHLRC1/malin (via the NHL repeats). Forms a complex with
CC       NHLRC1/malin and HSP70. Interacts with PPP1R3D; in the presence of
CC       NHLC1/malin the interaction leads to ubiquitination and autophagic
CC       degradation of PPP1R3D. Interacts (via the phosphatase domain)
CC       with MAPT/Tau; the interaction dephosphorylates MAPT. Isoform 2
CC       does not bind glycogen. Isoform 1 and isoform 2 interact to form a
CC       heterodimeric complex inactive as phosphatase in vitro. Active
CC       phosphatase isoform 7 interacts with isoform 1 or isoform 2 to
CC       form a heterodimeric complex inactive as phosphatase in vitro.
CC       Interacts with PRDM8 (PubMed:22961547).
CC       {ECO:0000269|PubMed:12782127, ECO:0000269|PubMed:12915448,
CC       ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:15930137,
CC       ECO:0000269|PubMed:16901901, ECO:0000269|PubMed:18070875,
CC       ECO:0000269|PubMed:19542233, ECO:0000269|PubMed:22961547,
CC       ECO:0000269|PubMed:23624058}.
CC   -!- INTERACTION:
CC       Q6VVB1:NHLRC1; NbExp=7; IntAct=EBI-2506661, EBI-6426628;
CC       Q9UQK1:PPP1R3C; NbExp=5; IntAct=EBI-2506661, EBI-2506727;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11001928,
CC       ECO:0000269|PubMed:11220751, ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:17908927, ECO:0000269|PubMed:18617530}.
CC       Note=Under glycogenolytic conditions localizes to the nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Endoplasmic reticulum. Cell
CC       membrane. Note=Primarily associated with polyribosomes at the
CC       endoplasmic reticulum, also found at the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:11883934}. Cell membrane
CC       {ECO:0000269|PubMed:11883934}. Nucleus
CC       {ECO:0000269|PubMed:11883934}. Note=Also found in the nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cytoplasm. Nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC       Name=1; Synonyms=A, LDH1, Laf331;
CC         IsoId=O95278-1; Sequence=Displayed;
CC       Name=2; Synonyms=B, C-terISO, Laf317;
CC         IsoId=O95278-2; Sequence=VSP_011017, VSP_011018;
CC         Note=Produced by alternative splicing.;
CC       Name=4; Synonyms=Laf152;
CC         IsoId=O95278-4; Sequence=VSP_011015, VSP_011016;
CC         Note=Produced by alternative splicing. May be due to an intron
CC         retention.;
CC       Name=5; Synonyms=Laf224;
CC         IsoId=O95278-5; Sequence=VSP_042496, VSP_042497;
CC         Note=Produced by alternative splicing.;
CC       Name=6; Synonyms=Laf88;
CC         IsoId=O95278-6; Sequence=VSP_042494;
CC         Note=Produced by alternative initiation at Met-244 of isoform 1.
CC         Transcript amplified but protein not detected.;
CC       Name=7; Synonyms=Laf177;
CC         IsoId=O95278-7; Sequence=VSP_042495;
CC         Note=Produced by alternative splicing. Active phosphatase.;
CC       Name=8;
CC         IsoId=O95278-8; Sequence=VSP_042493;
CC         Note=Produced by alternative splicing. No experimental
CC         confirmation available.;
CC       Name=9; Synonyms=POCR;
CC         IsoId=B3EWF7-1; Sequence=External;
CC         Note=Produced by alternative initiation. Arises due to the use
CC         of an alternative initiation codon in exon 1 out of frame with
CC         isoform 1 and results in a completely different isoform.;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, skeletal muscle, kidney,
CC       pancreas and brain. Isoform 4 is also expressed in the placenta.
CC       {ECO:0000269|PubMed:9771710}.
CC   -!- PTM: Polyubiquitinated by NHLRC1/malin.
CC       {ECO:0000269|PubMed:15930137}.
CC   -!- PTM: Phosphorylation on Ser-25 by AMPK affects the phosphatase
CC       activity of the enzyme and its ability to homodimerize and
CC       interact with NHLRC1, PPP1R3C or PRKAA2.
CC       {ECO:0000269|PubMed:21728993}.
CC   -!- DISEASE: Epilepsy, progressive myoclonic 2 (EPM2) [MIM:254780]: An
CC       autosomal recessive and severe form of adolescent-onset
CC       progressive epilepsy. Typically, as seizures increase in
CC       frequency, cognitive function declines towards dementia, and
CC       affected individuals die usually within 10 years after onset. EPM2
CC       occurs worldwide, but it is particularly common in the
CC       mediterranean countries of southern Europe and northern Africa, in
CC       southern India and in the Middle East. At the cellular level, it
CC       is characterized by accumulation of starch-like polyglucosans
CC       called Lafora bodies (LBs) that are most abundant in organs with
CC       the highest glucose metabolism: brain, heart, liver and skeletal
CC       muscle. Among other conditions involving polyglucosans, EPM2 is
CC       unique in that the inclusions are in neuronal dendrites but not
CC       axons and the forming polyglucosan fibrils are associated with the
CC       endoplasmic reticulum. {ECO:0000269|PubMed:11001928,
CC       ECO:0000269|PubMed:11175283, ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:12019207, ECO:0000269|PubMed:12560877,
CC       ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:14706656,
CC       ECO:0000269|PubMed:14722920, ECO:0000269|PubMed:15009235,
CC       ECO:0000269|PubMed:18311786, ECO:0000269|PubMed:9771710,
CC       ECO:0000269|PubMed:9931343}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAO15523.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=BAG51107.1; Type=Frameshift; Positions=223; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=The Lafora progressive myoclonus epilepsy
CC       mutation and polymorphism database;
CC       URL="http://projects.tcag.ca/lafora/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF084535; AAC83347.2; -; mRNA.
DR   EMBL; AF284580; AAG18377.1; -; mRNA.
DR   EMBL; AF454491; AAO15523.1; ALT_SEQ; mRNA.
DR   EMBL; AF454492; AAO15524.1; -; mRNA.
DR   EMBL; AF454493; AAO15525.1; -; mRNA.
DR   EMBL; AF454494; AAO15526.1; -; mRNA.
DR   EMBL; AK022721; BAG51107.1; ALT_FRAME; mRNA.
DR   EMBL; AK299497; BAG61454.1; -; mRNA.
DR   EMBL; AL023806; CAI21419.1; -; Genomic_DNA.
DR   EMBL; AL365193; CAI21419.1; JOINED; Genomic_DNA.
DR   EMBL; AL365193; CAI21675.1; -; Genomic_DNA.
DR   EMBL; AL023806; CAI21675.1; JOINED; Genomic_DNA.
DR   EMBL; CH471051; EAW47844.1; -; Genomic_DNA.
DR   EMBL; BC005286; AAH05286.1; -; mRNA.
DR   EMBL; BC070047; AAH70047.1; -; mRNA.
DR   EMBL; AJ130763; CAA10199.1; -; mRNA.
DR   EMBL; AJ130764; CAA10200.1; -; mRNA.
DR   CCDS; CCDS5206.1; -. [O95278-1]
DR   RefSeq; NP_001018051.1; NM_001018041.1. [O95278-2]
DR   RefSeq; NP_005661.1; NM_005670.3. [O95278-1]
DR   RefSeq; XP_006715627.1; XM_006715564.3. [O95278-5]
DR   RefSeq; XP_011534418.1; XM_011536116.1. [O95278-8]
DR   RefSeq; XP_016866789.1; XM_017011300.1. [O95278-7]
DR   RefSeq; XP_016866790.1; XM_017011301.1. [O95278-7]
DR   RefSeq; XP_016866791.1; XM_017011302.1. [O95278-7]
DR   UniGene; Hs.486696; -.
DR   PDB; 4R30; X-ray; 2.30 A; A/B/C/D=148-331.
DR   PDB; 4RKK; X-ray; 2.40 A; A/C=1-329.
DR   PDBsum; 4R30; -.
DR   PDBsum; 4RKK; -.
DR   ProteinModelPortal; O95278; -.
DR   SMR; O95278; -.
DR   BioGrid; 113679; 23.
DR   IntAct; O95278; 5.
DR   STRING; 9606.ENSP00000356489; -.
DR   BindingDB; O95278; -.
DR   ChEMBL; CHEMBL2311242; -.
DR   CAZy; CBM20; Carbohydrate-Binding Module Family 20.
DR   DEPOD; O95278; -.
DR   iPTMnet; O95278; -.
DR   PhosphoSitePlus; O95278; -.
DR   BioMuta; RNF213; -.
DR   PaxDb; O95278; -.
DR   PeptideAtlas; O95278; -.
DR   PRIDE; O95278; -.
DR   DNASU; 7957; -.
DR   Ensembl; ENST00000367519; ENSP00000356489; ENSG00000112425. [O95278-1]
DR   Ensembl; ENST00000611340; ENSP00000480268; ENSG00000112425. [O95278-8]
DR   Ensembl; ENST00000618445; ENSP00000480339; ENSG00000112425. [O95278-2]
DR   GeneID; 7957; -.
DR   KEGG; hsa:7957; -.
DR   UCSC; uc003qkw.4; human. [O95278-1]
DR   CTD; 7957; -.
DR   DisGeNET; 7957; -.
DR   GeneCards; EPM2A; -.
DR   GeneReviews; EPM2A; -.
DR   HGNC; HGNC:3413; EPM2A.
DR   HPA; HPA053643; -.
DR   HPA; HPA055468; -.
DR   MalaCards; EPM2A; -.
DR   MIM; 254780; phenotype.
DR   MIM; 607566; gene.
DR   neXtProt; NX_O95278; -.
DR   OpenTargets; ENSG00000112425; -.
DR   Orphanet; 501; Lafora disease.
DR   PharmGKB; PA27832; -.
DR   eggNOG; KOG1716; Eukaryota.
DR   eggNOG; COG2453; LUCA.
DR   GeneTree; ENSGT00390000010101; -.
DR   HOGENOM; HOG000285975; -.
DR   HOVERGEN; HBG051493; -.
DR   KO; K14165; -.
DR   OMA; RKVQYFV; -.
DR   OrthoDB; EOG091G0GBM; -.
DR   PhylomeDB; O95278; -.
DR   TreeFam; TF332841; -.
DR   BRENDA; 3.1.3.16; 2681.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   Reactome; R-HSA-3785653; Myoclonic epilepsy of Lafora.
DR   SIGNOR; O95278; -.
DR   ChiTaRS; EPM2A; human.
DR   GenomeRNAi; 7957; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112425; -.
DR   CleanEx; HS_EPM2A; -.
DR   ExpressionAtlas; O95278; baseline and differential.
DR   Genevisible; O95278; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005844; C:polysome; IDA:UniProtKB.
DR   GO; GO:0019203; F:carbohydrate phosphatase activity; EXP:Reactome.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008138; F:protein tyrosine/serine/threonine phosphatase activity; IEA:InterPro.
DR   GO; GO:2001070; F:starch binding; IEA:InterPro.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0005978; P:glycogen biosynthetic process; TAS:Reactome.
DR   GO; GO:0005977; P:glycogen metabolic process; NAS:UniProtKB.
DR   GO; GO:0046959; P:habituation; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; IEA:Ensembl.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IEA:Ensembl.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR013784; Carb-bd-like_fold.
DR   InterPro; IPR002044; CBM_fam20.
DR   InterPro; IPR000340; Dual-sp_phosphatase_cat-dom.
DR   InterPro; IPR024950; DUSP.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   InterPro; IPR020422; TYR_PHOSPHATASE_DUAL_dom.
DR   PANTHER; PTHR10159; PTHR10159; 1.
DR   Pfam; PF00686; CBM_20; 1.
DR   Pfam; PF00782; DSPc; 1.
DR   SMART; SM01065; CBM_2; 1.
DR   SMART; SM00195; DSPc; 1.
DR   SUPFAM; SSF49452; SSF49452; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS51166; CBM20; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50054; TYR_PHOSPHATASE_DUAL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing; Autophagy;
KW   Carbohydrate metabolism; Cell membrane; Complete proteome; Cytoplasm;
KW   Disease mutation; Endoplasmic reticulum; Epilepsy;
KW   Glycogen metabolism; Hydrolase; Membrane; Nucleus; Phosphoprotein;
KW   Polymorphism; Protein phosphatase; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN         1    331       Laforin.
FT                                /FTId=PRO_0000094838.
FT   DOMAIN        1    124       CBM20. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00594}.
FT   DOMAIN      243    311       Tyrosine-protein phosphatase.
FT   ACT_SITE    266    266       Phosphocysteine intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10044,
FT                                ECO:0000269|PubMed:11739371}.
FT   SITE        329    329       Required for homodimerization.
FT   MOD_RES      25     25       Phosphoserine; by AMPK.
FT                                {ECO:0000269|PubMed:21728993}.
FT   VAR_SEQ       1    243       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042494.
FT   VAR_SEQ       1    159       MRFRFGVVVPPAVAGARPELLVVGSRPELGRWEPRGAVRLR
FT                                PAGTAAGDGALALQEPGLWLGEVELAAEEAAQDGAEPGRVD
FT                                TFWYKFLKREPGGELSWEGNGPHHDRCCTYNENNLVDGVYC
FT                                LPIGHWIEATGHTNEMKHTTDFYFNIAGHQAMHYSR -> M
FT                                IFNK (in isoform 7).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042495.
FT   VAR_SEQ       1    138       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_042493.
FT   VAR_SEQ     102    199       NGPHHDRCCTYNENNLVDGVYCLPIGHWIEATGHTNEMKHT
FT                                TDFYFNIAGHQAMHYSRILPNIWLGSCPRQVEHVTIKLKHE
FT                                LGITAVMNFQTEWDIV -> IASRRLPPAQSGSSGPHPQPG
FT                                PRPRAGPAGPGGARPGLFARVPAHSPGDLG (in
FT                                isoform 4). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_011015.
FT   VAR_SEQ     160    293       Missing (in isoform 5). {ECO:0000305}.
FT                                /FTId=VSP_042496.
FT   VAR_SEQ     200    331       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_011016.
FT   VAR_SEQ     294    331       YFLMAKRPAVYIDEEALARAQEDFFQKFGKVRSSVCSL ->
FT                                PSTDAAPGGVPAACAAGEGTHRVRALQRWGGPLHRGCLRLA
FT                                PVCDGLESEEGAVFPHGQEAGCLH (in isoform 5).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042497.
FT   VAR_SEQ     310    320       LARAQEDFFQK -> ASQDTFPL (in isoform 2).
FT                                {ECO:0000303|PubMed:9771710,
FT                                ECO:0000303|PubMed:9931343}.
FT                                /FTId=VSP_011017.
FT   VAR_SEQ     321    331       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9771710,
FT                                ECO:0000303|PubMed:9931343}.
FT                                /FTId=VSP_011018.
FT   VARIANT      25     25       S -> P (in EPM2; atypical form; does not
FT                                affect glycogen binding).
FT                                {ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14706656}.
FT                                /FTId=VAR_019465.
FT   VARIANT      28     28       E -> K (in EPM2; does not affect glycogen
FT                                binding). {ECO:0000269|PubMed:14706656}.
FT                                /FTId=VAR_019466.
FT   VARIANT      32     32       W -> G (in EPM2; affects phosphatase
FT                                activity; abolishes glycogen binding;
FT                                disrupts the interaction with PPP1R3C;
FT                                dbSNP:rs104893955).
FT                                {ECO:0000269|PubMed:11739371,
FT                                ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:14706656}.
FT                                /FTId=VAR_019467.
FT   VARIANT      46     46       A -> P (does not affect glycogen binding;
FT                                dbSNP:rs374338349).
FT                                {ECO:0000269|PubMed:11735300,
FT                                ECO:0000269|PubMed:14706656,
FT                                ECO:0000269|PubMed:16021330}.
FT                                /FTId=VAR_019468.
FT   VARIANT      84     84       F -> L (in EPM2; affects phosphatase
FT                                activity and glycogen binding; disrupts
FT                                the interaction with PPP1R3C).
FT                                {ECO:0000269|PubMed:11175283,
FT                                ECO:0000269|PubMed:14532330}.
FT                                /FTId=VAR_019469.
FT   VARIANT      88     88       F -> L (in EPM2; does not affect glycogen
FT                                binding). {ECO:0000269|PubMed:14706656}.
FT                                /FTId=VAR_019470.
FT   VARIANT      91     91       R -> P (in EPM2; atypical form; learning
FT                                difficuties with childhood-onset).
FT                                {ECO:0000269|PubMed:14722920,
FT                                ECO:0000269|PubMed:15009235}.
FT                                /FTId=VAR_019471.
FT   VARIANT     108    108       R -> C (in EPM2; loss of phosphatase
FT                                activity; reduced self-interaction
FT                                capacity; disrupts the interaction with
FT                                PPP1R3C; dbSNP:rs137852915).
FT                                {ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:9771710}.
FT                                /FTId=VAR_019472.
FT   VARIANT     114    114       E -> D. {ECO:0000269|PubMed:9771710}.
FT                                /FTId=VAR_019473.
FT   VARIANT     140    140       K -> N (in EPM2).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046383.
FT   VARIANT     148    148       N -> Y (in EPM2).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046384.
FT   VARIANT     171    171       R -> H (in EPM2; results in ubiquitin-
FT                                positive perinuclear aggregates; may
FT                                affect proper folding;
FT                                dbSNP:rs137852916).
FT                                {ECO:0000269|PubMed:11001928,
FT                                ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14722920,
FT                                ECO:0000269|PubMed:9931343}.
FT                                /FTId=VAR_019474.
FT   VARIANT     187    187       T -> A (in EPM2; abolishes interaction
FT                                with NHLRC1).
FT                                {ECO:0000269|PubMed:12560877}.
FT                                /FTId=VAR_019475.
FT   VARIANT     194    194       T -> I (in EPM2; results in ubiquitin-
FT                                positive perinuclear aggregates; loss of
FT                                phosphatase activity; affects glycogen
FT                                binding; reduced self-interaction
FT                                capacity; abolishes interaction with
FT                                NHLRC1, PPP1R3C and PRKAA2; no effect on
FT                                phosphorylation of protein;
FT                                dbSNP:rs375544596).
FT                                {ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:9931343}.
FT                                /FTId=VAR_019476.
FT   VARIANT     210    210       E -> K (in EPM2).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046385.
FT   VARIANT     240    240       G -> S (in EPM2; very slight loss of
FT                                phosphatase activity; does not affect
FT                                glycogen binding; disrupts the
FT                                interaction with PPP1R3C).
FT                                {ECO:0000269|PubMed:11175283,
FT                                ECO:0000269|PubMed:14532330}.
FT                                /FTId=VAR_019477.
FT   VARIANT     279    279       G -> S (in EPM2; results in ubiquitin-
FT                                positive perinuclear aggregates; loss of
FT                                phosphatase activity; affects glycogen
FT                                binding; disrupts the interaction with
FT                                PPP1R3C; dbSNP:rs137852917).
FT                                {ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:14722920,
FT                                ECO:0000269|PubMed:9771710,
FT                                ECO:0000269|PubMed:9931343}.
FT                                /FTId=VAR_019478.
FT   VARIANT     293    293       Q -> L (in EPM2; results in ubiquitin-
FT                                positive perinuclear aggregates; may
FT                                affect proper folding; loss of
FT                                phosphatase activity; affects glycogen
FT                                binding; disrupts the interaction with
FT                                PPP1R3C; dbSNP:rs796052427).
FT                                {ECO:0000269|PubMed:11001928,
FT                                ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:9771710}.
FT                                /FTId=VAR_019479.
FT   VARIANT     294    294       Y -> N (in EPM2; results in ubiquitin-
FT                                positive perinuclear aggregates; loss of
FT                                phosphatase activity; affects glycogen
FT                                binding; disrupts the interaction with
FT                                PPP1R3C). {ECO:0000269|PubMed:12019207,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:9931343}.
FT                                /FTId=VAR_019480.
FT   VARIANT     301    301       P -> L (in EPM2; loss of phosphatase
FT                                activity; affects glycogen binding;
FT                                disrupts the interaction with PPP1R3C;
FT                                dbSNP:rs796052428).
FT                                {ECO:0000269|PubMed:11175283,
FT                                ECO:0000269|PubMed:14532330}.
FT                                /FTId=VAR_019481.
FT   VARIANT     310    310       L -> W (in EPM2; alters the subcellular
FT                                localization of isoform 1; does not
FT                                affect homodimerization of isoform 1 but
FT                                prevents heterodimerization of isoform 1
FT                                and isoform 2).
FT                                {ECO:0000269|PubMed:18311786}.
FT                                /FTId=VAR_046386.
FT   MUTAGEN      25     25       S->A: Partial loss of phosphatase
FT                                activity. Abolishes homodimerization.
FT                                Abolishes interaction with NHLRC1,
FT                                PPP1R3C and PRKAA2. Does not affect
FT                                glycogen binding. Reduces stability of
FT                                the protein.
FT                                {ECO:0000269|PubMed:21728993}.
FT   MUTAGEN      25     25       S->D: Partial loss of phosphatase
FT                                activity. Increases interaction with
FT                                NHLRC1. Does not affect interaction with
FT                                NHLRC1, PPP1R3C or PRKAA2. Does not
FT                                affect binding to carbohydrate. Does not
FT                                affect homodimerization.
FT                                {ECO:0000269|PubMed:21728993}.
FT   MUTAGEN      87     87       K->A: Partial loss of phosphatase
FT                                activity. Abolishes glycogen binding.
FT                                {ECO:0000269|PubMed:11739371}.
FT   MUTAGEN     109    110       CC->SS: No effect on homodimerization or
FT                                carbohydrate binding. Decreased
FT                                phosphatase activity.
FT                                {ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     123    123       C->S: No effect on homodimerization or
FT                                carbohydrate binding. Decreased
FT                                phosphatase activity.
FT                                {ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     168    168       S->A,D: Abolishes interaction with
FT                                NHLRC1. {ECO:0000269|PubMed:21728993}.
FT   MUTAGEN     169    169       C->S: No effect on homodimerization or
FT                                carbohydrate binding. Decreased
FT                                phosphatase activity.
FT                                {ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     187    187       T->D: Abolishes interaction with NHLRC1.
FT                                {ECO:0000269|PubMed:21728993}.
FT   MUTAGEN     194    194       T->D: Does not affect interaction with
FT                                NHLRC1, PPP1R3C or PRKAA2.
FT                                {ECO:0000269|PubMed:21728993}.
FT   MUTAGEN     205    205       C->S: No effect on homodimerization or
FT                                carbohydrate binding. Decreased
FT                                phosphatase activity.
FT                                {ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     235    235       D->A: Loss of phosphatase activity. Does
FT                                not affect glycogen binding.
FT                                {ECO:0000269|PubMed:14532330}.
FT   MUTAGEN     250    250       C->S: No effect on homodimerization or
FT                                carbohydrate binding. Decreased
FT                                phosphatase activity.
FT                                {ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     266    266       C->S: Complete loss of phosphatase
FT                                activity. Does not affect glycogen
FT                                binding. Does not affect self-
FT                                interaction. Increases the interaction
FT                                with PPP1R3C.
FT                                {ECO:0000269|PubMed:11739371,
FT                                ECO:0000269|PubMed:14532330,
FT                                ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     329    331       Missing: Fails to homodimerize. Does not
FT                                affect carbohydrate binding or
FT                                phosphatase activity.
FT                                {ECO:0000269|PubMed:23922729}.
FT   MUTAGEN     329    329       C->S: Fails to homodimerize. Does not
FT                                affect carbohydrate binding, interaction
FT                                with NHLRC1, phosphatase activity, or
FT                                ubiquitination by NHLRC1.
FT                                {ECO:0000269|PubMed:23922729}.
FT   CONFLICT    193    193       Q -> K (in Ref. 8; AAH70047).
FT                                {ECO:0000305}.
FT   CONFLICT    248    248       A -> P (in Ref. 4; AAO15523).
FT                                {ECO:0000305}.
FT   CONFLICT    258    258       K -> E (in Ref. 5; BAG61454).
FT                                {ECO:0000305}.
FT   CONFLICT    294    294       Y -> H (in Ref. 5; BAG61454).
FT                                {ECO:0000305}.
FT   STRAND        1      9       {ECO:0000244|PDB:4RKK}.
FT   HELIX        11     14       {ECO:0000244|PDB:4RKK}.
FT   STRAND       19     26       {ECO:0000244|PDB:4RKK}.
FT   HELIX        27     29       {ECO:0000244|PDB:4RKK}.
FT   TURN         30     32       {ECO:0000244|PDB:4RKK}.
FT   HELIX        34     36       {ECO:0000244|PDB:4RKK}.
FT   STRAND       58     67       {ECO:0000244|PDB:4RKK}.
FT   STRAND       84     91       {ECO:0000244|PDB:4RKK}.
FT   STRAND       97    103       {ECO:0000244|PDB:4RKK}.
FT   HELIX       104    106       {ECO:0000244|PDB:4RKK}.
FT   STRAND      108    110       {ECO:0000244|PDB:4RKK}.
FT   HELIX       114    116       {ECO:0000244|PDB:4RKK}.
FT   STRAND      121    123       {ECO:0000244|PDB:4RKK}.
FT   HELIX       138    151       {ECO:0000244|PDB:4RKK}.
FT   STRAND      157    161       {ECO:0000244|PDB:4R30}.
FT   STRAND      164    167       {ECO:0000244|PDB:4R30}.
FT   HELIX       173    177       {ECO:0000244|PDB:4R30}.
FT   HELIX       178    183       {ECO:0000244|PDB:4R30}.
FT   STRAND      188    191       {ECO:0000244|PDB:4R30}.
FT   HELIX       195    201       {ECO:0000244|PDB:4R30}.
FT   HELIX       203    205       {ECO:0000244|PDB:4R30}.
FT   STRAND      208    210       {ECO:0000244|PDB:4R30}.
FT   HELIX       214    223       {ECO:0000244|PDB:4R30}.
FT   STRAND      227    230       {ECO:0000244|PDB:4R30}.
FT   HELIX       238    258       {ECO:0000244|PDB:4R30}.
FT   STRAND      262    265       {ECO:0000244|PDB:4R30}.
FT   HELIX       271    283       {ECO:0000244|PDB:4R30}.
FT   HELIX       289    296       {ECO:0000244|PDB:4R30}.
FT   STRAND      303    305       {ECO:0000244|PDB:4R30}.
FT   HELIX       307    321       {ECO:0000244|PDB:4R30}.
SQ   SEQUENCE   331 AA;  37158 MW;  DD79F917262AB458 CRC64;
     MRFRFGVVVP PAVAGARPEL LVVGSRPELG RWEPRGAVRL RPAGTAAGDG ALALQEPGLW
     LGEVELAAEE AAQDGAEPGR VDTFWYKFLK REPGGELSWE GNGPHHDRCC TYNENNLVDG
     VYCLPIGHWI EATGHTNEMK HTTDFYFNIA GHQAMHYSRI LPNIWLGSCP RQVEHVTIKL
     KHELGITAVM NFQTEWDIVQ NSSGCNRYPE PMTPDTMIKL YREEGLAYIW MPTPDMSTEG
     RVQMLPQAVC LLHALLEKGH IVYVHCNAGV GRSTAAVCGW LQYVMGWNLR KVQYFLMAKR
     PAVYIDEEAL ARAQEDFFQK FGKVRSSVCS L
//
